Eli Lilly is amplifying its calls for the FDA to intervene against unsafe compounded versions of its weight-loss drug Zepbound, following alarming safety warnings about impurities and untested additives in personalized tirzepatide products. The company has raised concerns over potential health risks linked to these formulations, urging a recall due to the dangers they pose to consumers. As it grapples with these regulatory challenges, Lilly is simultaneously investing $3 billion in China to bolster its production capacity for obesity treatments, signaling confidence in its market leadership amid increased competition.
“Eli Lilly amplified its calls on the Food and Drug Administration to crack down on companies making compounded versions of its obesity shot Zepbound, saying Thursday that formulations that include vitamin B12 may be 'dangerous' to patients.”
“Lilly added, warning that users 'should be aware that they may be using a potentially dangerous product with unknown risks.'”
“Eli Lilly has warned of high levels of an impurity in certain compounded versions of its blockbuster glucagon-like peptide-1 receptor agonist (GLP-1RA) tirzepatide.”
“The drugmaker said 'nothing is known' about the short- or long-term effects of this interaction in humans.”
“The company stated that we also urge the FDA to continue taking action against unlawful mass compounding of tirzepatide that puts the American public at risk.”
“Eli Lilly and Novo Nordisk NVO presently dominate the global obesity market. Mounjaro and Zepbound directly compete with NVO’s semaglutide medicines, Ozempic for T2D and Wegovy for obesity. Both companies derive a significant share of their revenues from these blockbuster GLP-1 therapies.”
“A few years ago, Novo Nordisk was the leader in the weight loss market. It has now lost that lead to its biggest rival, Eli Lilly, while it will face even more competition from other biotechs and pharma leaders in the next few years. The company's sales will decline in 2026 as well.”
“Eli Lilly and Company (NYSE:LLY) plans to invest $3 billion in China over the next decade, helping develop production capacity for its experimental type-2 diabetes and obesity treatment orforglipron.”
“It also plans to establish a localised manufacturing and supply system for oral solid dosage forms, according to the statement.”
“Eli Lilly is the market share leader in the GLP-1 weight loss market by a large amount. The company is likely to expand that lead if the U.S. Food & Drug Administration approves its oral GLP-1 drug candidate in 2026.”
“analysts give the stock a consensus price target suggesting it could grow by 25%. That's backed by the expectation of earnings growth of around 35% in the next 12 months.”
“One potential rival is Eli Lilly and Co, which previously expressed interest in the French biotech and could re-enter discussions once the exclusivity window closes.”
